U.S. Markets closed

Neovasc and Three Additional Medical Appliances & Equipment Stocks on Our Research Desk’s Radar

Stock Research Monitor: SNN, ARAY, and ACRX

LONDON, UK / ACCESSWIRE / June 18, 2018 / If you want a free Stock Review on NVCN sign up now at www.wallstequities.com/registration. On Friday, June 15, 2018, the NASDAQ Composite ended the trading session at 7,746.38, down 0.19%; the Dow Jones Industrial Average edged 0.34% lower, to finish at 25,090.48; and the S&P 500 closed at 2,779.66, slightly dropping 0.10%. US markets saw five out of nine sectors finishing the day in green and four in red. This Monday, WallStEquities.com has initiated reports coverage on the following Medical Appliances & Equipment equities: Neovasc Inc. (NASDAQ: NVCN), Smith & Nephew PLC (NYSE: SNN), Accuray Inc. (NASDAQ: ARAY), and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). All you have to do is sign up today for this free limited time offer by clicking the link below.



Richmond, Canada headquartered Neovasc Inc.'s stock finished Friday's session 1.81% higher at $0.03 with a total trading volume of 11.90 million shares. The Company's shares have advanced 6.31% in the last month. The stock is trading below its 50-day moving average by 19.29%. Additionally, shares of Neovasc, which develops, manufactures, and markets cardiovascular devices worldwide, have a Relative Strength Index (RSI) of 43.21. Get the full research report on NVCN for free by clicking below at:


Smith & Nephew

On Friday, shares in London, the UK headquartered Smith & Nephew PLC recorded a trading volume of 418,393 shares. The stock ended the session 0.14% higher at $36.88. The Company's shares have advanced 6.53% over the last twelve months. The stock is trading above its 200-day moving average by 1.02%. Moreover, shares of the Company, which designs, develops, and sells medical devices worldwide, have an RSI of 51.68. Free research on SNN can be accessed at:



Sunnyvale, California headquartered Accuray Inc.'s shares closed the day 7.45% lower at $4.35. The stock recorded a trading volume of 1.40 million shares, which is above its three months average volume of 514.34 thousand shares. The Company's shares have gained 6.10% over the last twelve months. The stock is trading below its 50-day moving average by 8.12%. Additionally, shares of Accuray, which designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body, have an RSI of 40.89. Sign up today for the free research report on ARAY at:


AcelRx Pharmaceuticals

Shares in Redwood City, California headquartered AcelRx Pharmaceuticals Inc. finished 1.82% higher at $4.20. The stock recorded a trading volume of 928,799 shares, which is above its three months average volume of 537.63 thousand shares. The Company's shares have advanced 37.70% in the last month, 102.41% in the previous three months, and 82.61% over the last twelve months. The stock is trading above its 50-day and 200-day moving averages by 49.07% and 67.74%, respectively. Furthermore, shares of AcelRx Pharma, which focuses on the development and commercialization of therapies for the treatment of acute pain, have an RSI of 83.88. Wall St. Equities' research coverage also includes the downloadable free report on ACRX at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities